A European engineering company will develop a project for a new plant for the production of active pharmaceutical substances in St. Petersburg
Glatt, Germany, a world leader in integrated technological solutions for pharmaceutical industry, is going to develop a concept project for a plant of active pharmaceutical ingredients (API) of the Active Component company in Pushkinsky district of Saint Petersburg.
The new production facility with an area of 20,000 square meters will be one of the largest and most modern in Europe. The plant capacity will be up to 100 tons of APIs per year. The amount of investments into the project is 2 billion rubles. Apart from classical synthesis substances, the facility will manufacture antitumor substances (cytostatics), and hormonal substances of peptide synthesis. The first stage of the plant with a capacity of up to 40 tons of finished products per year will be launched at the end of 2018, a year earlier than planned.
In accordance with the agreement with Active Component, Glatt, Germany will make a concept project of the whole facility and develop working documentation for the first stage with the area of 3,000 square meters.
Looking back, at the end of 2017, Active Component signed another agreement for development of a concept project and design of the first stage of the plant with a large Russian chemical and pharmaceutical holding, Pharmkontrakt Group. Both companies must present the developed concept projects to the Customer by July 2018.
“A new plant makes a new step for Active Component, a reliable platform for strengthening business. We intend to create the top production facility that meets highest world standards. The fact that a large European corporation with half a century of experience in developing effective technological and production solutions will be beneficial for our project. One Business Division of Glatt specializes in design of API manufacturing plants. It is a great competitive advantage of the German designer, there are few such companies in the world,” says Alexander Semenov, President of Active Component.